Member Info for smkr

When you put it like this Llama .. the sky could be the limit with this one

Just google Dennis Purcell, look at his company Aisling Capital that he founded and grew. Why on earth would he be our Chairman ? Think big pharma he can introduce when this stage 3 progresses further..

I mean what price do you put on a treatment backed by the NHS in late stage, where stage 2 trials peeps went from 2% staying sober to 86% after treatment?

Nearly ready.. they want 0.15 for 13m shares. like less than 20 grand.. tightening them away we go

Interesting development at kp2 there today. they need a good port to export that potash

Decent volume again. 150m plus. will be breaking out soon

Some snippets from Proactive interview

"The results of the phase two for that program were groundbreaking," Tennyson said, highlighting that participants improved from 2% sobriety to 86% six months post-treatment.

The phase Ill trial is being conducted in partnership with the UK Department of Health at an unusually low cost of £800,000, a figure Tennyson noted is "unheard of really, in the biopharmaceutical industry."

The trial is being carried out within the NHS and supported by UK addiction specialists and the Department of Health and Social Care, adding national relevance to the program.

That program is in phase three, which, for your audience to understand, is the final stage in clinical research before being able, subject to being successful, to apply for approval to market your drug. The results of the phase two for that program were groundbreaking, Stephen. And this is really important — people coming onto that trial were sober 2% of the time. So they were sober seven days a year.

Those that went through the active arm of the trial achieved, on average, 86% sobriety in the six months post-treatment. So to move from 2% sobriety to 86% sobriety in the six months post-treatment is really unheard of in the treatment of this debilitating disease of alcohol addiction.

That trial is now in phase three, and it's been executed through a partnership now between Solvonis and the UK Department of Health.

Through that partnership, the trial is actually being executed at a very, very low cost. The cost to Solvonis is only £800,000 sterling for a phase three, potentially to finish a trial, is unheard of really in the biopharmaceutical industry. What's really important for us is that the trial is being executed in the NHS in the UK. So all in all, for Solvonis, which is a UK-incorporated, London-listed biotech, it's really important for us having that UK-relevant phase three trial for alcohol use disorder being executed in the NHS, with many of the addiction key opinion leaders in England active in the trial, being supported by the UK Department of Health and Social Care. So we're really pleased to have that asset now within Solvonis. And we're very excited about the potential for that program.

The Colombo Stock Exchange listing of Redgate. it’s in the RNS, and probably was crucial to have a local partner involved

Https://x.com/serialinvestor8/status/1930935079708090456?s=46

Https://x.com/serialinvestor8/status/1930935079708090456?s=46

Tightened right up .. only 8 grand available to buy then no quotes

SVN-001 - a Phase 3-stage, proprietary combination of intravenous ketamine and relapse-prevention cognitive behavioural therapy ("CBT") for severe Alcohol Use Disorder ("AUD"), currently being evaluated across eight NHS Trusts in the UK. The trial is co-funded by the Medical Research Council ("MRC"), the National Institute for Health and Care Research ("NIHR") and Solvonis.

The global addiction treatment market size is calculated at USD 9.97 billion in 2025 and is forecasted to reach around USD 16.22 billion by 2034, accelerating at a CAGR of 5.56% from 2025 to 2034. The North America market size surpassed USD 3.49 billion in 2024 and is expanding at a CAGR of 5.57% during the forecast period.

Mark it. 5 bagger incoming

Dennis Purcell, a prominent figure in the biotech and pharmaceutical investment landscape, has been instrumental in numerous high-profile transactions throughout his career. As the Founder and Senior Advisor at Aisling Capital, and formerly the Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist), he has overseen and participated in over 200 completed transactions, supervising more than $15 billion in financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries .

Aton Pharma: Served on the board; the company was acquired by Merck & Co.

Bridge Pharmaceuticals: Board member; the company was acquired by Pharmaron.

Same DV. This has the ingredients

Purcell is top drawer, a serial winner. Back the legit guys

With a mission to tackle the global crisis of addiction and mental health disorders, this company is backed by an elite leadership team, a game-changing product pipeline, and a fast-track pathway to the U.S. market.

At the core of Solvonis’s vision is SVN-002, a revolutionary treatment for moderate to severe alcohol use disorder. This isn’t just another pill — it's a novel oral thin film delivery of esketamine, combined with structured psycho-social support. The innovation here is twofold: a proprietary drug delivery system that enhances absorption and effect, and a dual-therapy approach designed to maximise real-world patient outcomes.

The FDA has already given its nod of approval in a positive pre-IND meeting, supporting the use of the efficient 505(b)(2) regulatory pathway — meaning this product could hit the market faster and with less cost than traditional drug development routes.

Alcohol use disorder affects over 14 million adults in the U.S. alone, with limited treatment options and a high relapse rate. SVN-002 offers a completely new approach — one that could completely disrupt the current treatment model.

What truly sets Solvonis apart is its leadership. Prof. David Nutt, the company’s Chief Scientific Advisor, is a global authority on neuropsychopharmacology, regularly seen on TV and widely respected across academic and clinical circles. With over 500 research papers and 36 books to his name, his involvement adds instant credibility — and more importantly, visionary insight.

Then there’s Dennis Purcell, Chairman of Solvonis (LON:SVNS) and a titan of the biotech industry. Having led over $15 billion in deals, Purcell knows how to scale high-potential biotech businesses into billion-dollar winners. He’s made it clear: Solvonis is targeting some of the most pressing medical needs of our time — PTSD, depression, addiction — and they have the technology to deliver real change. He believes the company’s drug delivery and polymer modification platform will be key to driving major partnerships with pharma and biotech giants.

The fog has cleared … time to move up

Blue! finally..

Vortex is designed to integrate seamlessly with a variety of partners, including digital wallets, payment service providers, and traditional ramping services.

Since its launch in Europe and Brazil, Vortex has achieved over $1 million in transaction volumes, with more than half of that occurring in May 2025 alone. This early traction underscores the platform’s potential in the rapidly growing cross-border stablecoin payments market, which was valued at $27 billion in 2023 and is projected to reach $137 billion by 2028.

With plans to expand into key markets such as Argentina and further integrate with major blockchain networks like Ethereum, Polygon, and Polkadot, Vortex is poised to capitalize on the growing demand for efficient, low-cost cross-border payment solutions. Its innovative approach to bridging stablecoins with local fiat currencies positions it as a transformative platform in the global financial ecosystem.